Biofil Chem & Pharma Ltd
NSE: BIOFILCHEM · Pharmaceuticals · sector
₹28.03NSE close 2026-10-26
Key numbers
Market cap₹46 cr
Price₹28.03
52w high / low₹46 / ₹26
P/E93.4xSector median 27.9x
P/B2.1xSector median 2.9x
Book value₹13.2
Dividend yield–Sector median 0.48%
ROE2.4%Sector median 11.7%
ROCE3.4%Sector median 12.3%
OPM2.3%Sector median 14.0%
Debt / equity0.14xSector median 0.16x
EV/EBITDA58.1xSector median 18.6x
Interest cover548.5x
Current ratio1.73x
Sales growth 3y-1.9%Sector median +9.6%
Profit growth 3y+70.7%Sector median +13.3%
PEG1.16x
Last 12 months to Jun 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Cash ₹3 cr vs borrowings ₹3 cr (FY26): cash is higher (net cash).
- Operating profit covered interest 548.5x in the last 12 months.
- No promoter shares are pledged.
- Operating cash flow was below net profit in 4 of the last 5 years (FY26, FY25, FY23, FY22).
- Revenue was higher than a year earlier in 2 of the last 4 quarters.
- Other income was 65% of net profit in the last 12 months.
- Debtor days went from 301 (FY24) to 355 (FY26).
- No dividend in the last 5 financial years.
- Price ₹28.03 on 2026-10-26: -39.5% from the 52-week high, +9.5% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹83.51 · low ₹27.55
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 14 | 8 | 6 | 14 | 1 | 8 | 12 |
| EBITDA | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| OPM % | 5.0% | 2.2% | 1.3% | 0.2% | 0.8% | 10.5% | 5.7% | 1.1% |
| Other income | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 |
| Net profit | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| EPS (₹) | 0.01 | 0.10 | 0.12 | 1.48 | 0.05 | 0.05 | 0.13 | 0.07 |
| Revenue YoY | +461.8% | -93.9% | -9.3% | +92.1% | ||||
| Profit YoY | +300.0% | -50.0% | +5.0% | -95.4% |
Standalone figures where filed. Latest quarter Jun 2026.
Profit & loss (yearly)
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 | TTM |
|---|---|---|---|---|---|---|
| Revenue | 22 | 30 | 40 | 33 | 28 | 34 |
| EBITDA | 1 | 1 | 1 | 1 | 1 | 1 |
| Net profit | 1 | 1 | 1 | 1 | 3 | 0 |
| EPS (₹) | 0.44 | 0.29 | 0.44 | 0.34 | 1.71 | 0.30 |
| Revenue growth | +34.2% | +33.3% | -16.6% | -15.0% | +9.3% | |
| Profit growth | -20.0% | +26.8% | -21.1% | +398.2% | -82.7% | |
| Dividend / share (₹) | – | – | – | – | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | -1.9% | -4.5% | +9.3% |
| Net profit | +70.7% | +17.5% | -82.7% |
| EPS | +80.7% | +17.6% | – |
| Share price | – | -33.6% (2y) | -26.8% |
Balance sheet
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Shareholders' equity | – | 17 | 18 | 19 | 22 |
| Borrowings | – | 1 | 0 | 0 | 3 |
| Cash & equivalents | – | 0 | 2 | 0 | 3 |
| Total assets | – | 31 | 47 | 51 | 43 |
| Fixed assets | – | 9 | 9 | 8 | 7 |
| Investments | – | 0 | 0 | 0 | 0 |
| Receivables | – | 20 | 33 | 38 | 28 |
| Inventory | – | 1 | 3 | 3 | 4 |
| Payables | – | 13 | 28 | 31 | 17 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Cash from operations | -0 | -0 | 2 | -2 | -1 |
| Cash from investing | -0 | -0 | -0 | -0 | 1 |
| Cash from financing | -0 | 0 | -0 | 0 | 3 |
| Capex | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -0 | -0 | 2 | -2 | -1 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| ROE % | – | 3.2% | 3.9% | 3.0% | 12.9% |
| ROCE % | – | 4.7% | 4.9% | 4.0% | 14.1% |
| Debtor days | – | 249 | 301 | 419 | 355 |
| Inventory days | – | 16 | 25 | 40 | 56 |
| Payable days | – | 168 | 268 | 367 | 240 |
| Cash conversion cycle (days) | – | 97 | 58 | 92 | 171 |
| Working capital days | – | 105 | 90 | 117 | 195 |
Shareholding
| Holder | % (2026-09-30) |
|---|---|
| Promoters | 46.79% |
| DIIs | 0.08% |
| Public (non-institutions) | 53.13% |
| Quarter | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters % | 46.82% | 46.82% | 46.82% | 46.79% | 46.79% | 46.79% | 46.79% | 46.79% |
| Promoter group | % |
|---|---|
| Scope Finance Company Private Limited | 13.90% |
| MID (India) Pharmaceuticals PVT Ltd | 7.22% |
| Cyano Finance and Sales PVT. Ltd. | 5.39% |
| Meena Shah | 4.06% |
| Niyati Shah | 4.05% |
| Ketan Shah | 3.03% |
| Sandeep Shah | 2.60% |
| Romil Shah | 2.35% |
| Smitesh Sanalal Shah | 1.15% |
| Trupti Shah | 0.63% |
| Ritu Shah | 0.55% |
| Manali Simon | 0.54% |
| Meet Shah | 0.54% |
| Rohan Shah | 0.40% |
| Kiran Shah | 0.39% |
| Public holders above 1% | % |
|---|---|
| Starline Equifin Private Limited | 7.07% |
| KSL and Industries Limited | 1.89% |
| Kishor Himmatsinh Jhala | 1.22% |
| GOM Industries Ltd | 1.11% |
24,660 shareholders. Pledged: 0.00% of promoter shares.
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| BIOFILCHEM | ₹46 cr | 93.4x | 2.1x | 2.4% | 3.4% | 2.3% | -1.9% | – |
Business segments (FY26)
| Segment | Revenue | Share | EBIT | Margin |
|---|---|---|---|---|
| Pharma Division | ₹19 cr | 66.8% | ₹2 cr | 12.4% |
| Chemical Division | ₹9 cr | 33.2% | ₹1 cr | 10.0% |
Dividends & corporate actions
| Ex-date | Action | Detail |
|---|---|---|
| 2024-09-23 | Other | Annual General Meeting |
| 2023-09-20 | Other | Annual General Meeting |
| 2022-09-21 | Other | Annual General Meeting |
| 2021-09-17 | Other | Annual General Meeting |
| 2020-09-21 | Other | Annual General Meeting |
| 2019-09-18 | Other | Annual General Meeting |
| 2018-09-18 | Other | Annual General Meeting |
| 2017-09-14 | Other | Annual General Meeting |
| 2016-09-22 | Other | Annual General Meeting |
| 2015-09-16 | Other | Annual General Meeting |
| 2014-09-18 | Other | Annual General Meeting |
| 2013-09-19 | Other | Annual General Meeting |
| 2012-09-20 | Other | Annual General Meeting |
| 2011-09-22 | Other | Annual General Meeting |
| 2009-09-23 | Other | Annual General Meeting |
| 2008-09-19 | Other | Annual General Meeting |
| 2007-09-20 | Other | Agm |
| 2006-09-21 | Other | Agm |
| 2005-09-22 | Other | Agm |
Documents
- Annual report FY26
- Annual report FY25
- Annual report FY24
- Annual report FY23
- Annual report FY22
- Announcements NSE filings
- Latest results (data file) XBRL
- Announcements BSE filings
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | BIOFILCHEM |
| BSE code | 524396 |
| ISIN | INE829A01014 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from NSE company filings (XBRL: Integrated Filing - Financials + financial results), NSE shareholding & pledge data; price = NSE close 2026-10-26.